Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Biguanide oral antidiabetic. Biguanides decrease hepatic neoglycogenesis and have little risk of hypoglycemia.
At the date of the last update we did not find any published data on its excretion in breast milk.
High risk of severe lactic acidosis. It has been withdrawn from the market in most countries of the world. (Yendapally 2020)
Oral anti-diabetic drugs are useless for treatment of diabetes type 1. For diabetes type 2, diet and exercise are advisable. Breastfeeding helps to lower glucemia level.
See below the information of this related product: